Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 11, 2015, Pages

  Pierro, Maria ^a   Thébaud, Bernard ^b,c,d   Soll, Roger ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CLINICAL PROTOCOL; EXPERIMENTAL DESIGN; HUMAN; INFANT; LUNG DYSPLASIA; MESENCHYMAL STEM CELL; NEWBORN MORTALITY; PATIENT SAFETY; PREMATURITY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THERAPY EFFECT;

EID: 85033490922     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011932     Document Type: Article

References (47)

1. Alagesan S, Griffin MD. Autologous and allogeneic mesenchymal stem cells in organ transplantation: what do we know about their safety and efficacy?. Current Opinion in Organ Transplantation 2014;19(1):65-72. [PUBMED: 24370985]
2. Anderson PJ, Doyle LW. Neurodevelopmental outcome of bronchopulmonary dysplasia. Seminars in Perinatology 2006;30(4):227-32. [PUBMED: 16860163]
3. Antunes MA, Laffey JG, Pelosi P, Rocco PR. Mesenchymal stem cell trials for pulmonary diseases. Journal of Cellular Biochemistry 2014;115(6):1023-32. [PUBMED: 24515922]
4. Aslam M, Baveja R, Liang OD, Fernandez-Gonzalez A, Lee C, Mitsialis SA, et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. American Journal of Respiratory and Critical Care Medicine 2009;180(11):1122-30. [PUBMED: 19713447]
5. Baker CD, Alvira CM. Disrupted lung development and bronchopulmonary dysplasia: opportunities for lung repair and regeneration. Current Opinion in Pediatrics 2014;26(3):306-14. [PUBMED: 24739494]
6. Batsali AK, Kastrinaki MC, Papadaki HA. Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications. Current Stem Cell Research & Therapy 2013;8(2):144-55. [PUBMED: 23279098]
7. Beam KS, Aliaga S, Ahlfeld SK, Cohen-Wolkowiez M, Smith PB, Laughon MM. A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants. Journal of Perinatology 2014;34(9):705-10. [PUBMED: 25010224]
8. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery 1978;187(1):1-7. [PUBMED: 413500]
9. Bellayr IH, Catalano JG, Lababidi S, Yang AX, Lo Surdo JL, Bauer SR, et al. Gene markers of cellular aging in human multipotent stromal cells in culture. Stem Cell Research & Therapy 2014;5(2):59. [PUBMED: 24780490]
10. Bhandari A, Panitch HB. Pulmonary outcomes in bronchopulmonary dysplasia. Seminars in Perinatology 2006;30(4):219-26. [PUBMED: 16860162]
11. Blau HM, Brazelton TR, Weimann JM. The evolving concept of a stem cell: entity or function?. Cell 2001;105(7):829-41. [PUBMED: 11439179]
12. Chang YS, Choi SJ, Sung DK, Kim SY, Oh W, Yang YS, et al. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells dose-dependently attenuates hyperoxia-induced lung injury in neonatal rats. Cell transplantation 2011;20(11-12):1843-54. [PUBMED: 23167961]
13. Chang YS, Ahn SY, Yoo HS, Sung SI, Choi SJ, Oh WI, et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. Journal of Pediatrics 2014;164(5):966-972.e6. [PUBMED: 24508444]
14. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. Journal of Cell Science 2006;119(Pt 11):2204-13. [PUBMED: 16684817]
15. Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birthweight infants. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD000501.pub3]
16. Dmitrieva RI, Minullina IR, Bilibina AA, Tarasova OV, Anisimov SV, Zaritskey AY. Bone marrow- and subcutaneous adipose tissue-derived mesenchymal stem cells: differences and similarities. Cell Cycle 2012;11(2):377-83. [PUBMED: 22189711]
17. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8(4):315-7. [PUBMED: 16923606]
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [PUBMED: 9310563]
19. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005;116(6):1353-60. [PUBMED: 16322158]
20. Farstad T, Bratlid D, Medbo S, Markestad T. Bronchopulmonary dysplasia - prevalence, severity and predictive factors in a national cohort of extremely premature infants. Acta Paediatrica 2011;100(1):53-8. [PUBMED: 20653607]
21. Gebler A, Zabel O, Seliger B. The immunomodulatory capacity of mesenchymal stem cells. Trends in Molecular Medicine 2012;18(2):128-34. [PUBMED: 22118960]
22. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
23. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15. [PUBMED: 21247734]
24. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [PUBMED: 21839614]
25. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE Working Group. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [PUBMED: 21803546]
26. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE Working Group. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [PUBMED: 21802903]
27. Higgins A, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
28. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Archives of Ophthalmology 2005;123(7):991-9. [PUBMED: 16009843]
29. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine 2001; Vol. 163, issue 7:1723-9. [PUBMED: 11401896]
30. Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L. Immunological characterization of multipotent mesenchymal stromal cells - The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 2013;15(9):1054-61. [PUBMED: 23602578]
31. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS one 2012;7(10):e47559. [PUBMED: 23133515]
32. Lapcharoensap W, Gage SC, Kan P, Profit J, Shaw GM, Gould JB, et al. Hospital variation and risk factors for bronchopulmonary dysplasia in a population-based cohort. JAMA Pediatrics 2015;169(2):e143676. [DOI: 10.1001/jamapediatrics.2014.3676]
33. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Experimental & Molecular Medicine 2013;45:e54. [PUBMED: 24232253]
34. National Institutes of Health. Report of Workshop on Bronchopulmonary Dysplasia. Washington, DC: National Institutes of Health 1979. NIH Publication No. 80-1660.
35. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1, 500 gm. Journal of Pediatrics 1978;92(4):529-34. [PUBMED: 305471]
36. Pierro M, Ionescu L, Montemurro T, Vadivel A, Weissmann G, Oudit G, et al. Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax 2013;68(5):475-84. [PUBMED: 23212278]
37. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
38. Schünemann H, Brozek J, Guyatt G, Oxman A (editors). GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from www.guidelinedevelopment.org/handbook.
39. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82(4):527-32. [PUBMED: 3174313]
40. Speer CP. Pulmonary inflammation and bronchopulmonary dysplasia. Journal of Perinatology 2006;26 Suppl 1:S57-62. [PUBMED: 16625227]
41. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010;126(3):443-56. [PUBMED: 20732945]
42. Sullivan MJ. Banking on cord blood stem cells. Nature reviews. Cancer 2008;8(7):555-63. [PUBMED: 18548085]
43. van Haaften T, Byrne R, Bonnet S, Rochefort GY, Akabutu J, Bouchentouf M, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. American Journal of Respiratory and Critical Care Medicine 2009;180(11):1131-42. [PUBMED: 19713449]
44. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One 2008;3(5):e2213. [PUBMED: 18493317]
45. Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. Journal of Perinatology 2003;23(6):451-6. [PUBMED: 13679930]
46. Walsh MC, Szefler S, Davis J, Allen M, Van Marter L, Abman S, et al. Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics 2006;117(3 Pt 2):S52-6.
47. Watterberg KL, American Academy of Pediatrics. Committee on Fetus and Newborn. Policy statement - postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010;126(4):800-8. [PUBMED: 20819899]